Welcome to MAPS canada

The Multidisciplinary Association for Psychedelic Studies (MAPS) Canada is committed to planning, conducting and publishing scientific research and education supporting the beneficial uses of psychedelic medicines, including treatment for medical conditions, neuroscience, creativity and spirituality.  

Supported by rigorous scientific evaluation of risks and benefits and through partnerships with academic, health, hospital and community organizations, MAPS Canada envisions a world where psychedelic therapies are legally and widely available.

We’ve just launched a new webinar series! 

 

The series will consist of 14 episodes, each containing a presentation by someone in the rapidly advancing field of psychedelics. Our goal with the webinar series would be to bring forward important voices in the psychedelic sphere to discuss all sorts of topics related to psychedelics and the path to legalization. We’ll have content on the sacred language of plant medicines, MDMA-Assisted Psychotherapy, visionary art and everything in between!

Play Video

Psychedelics are back and they offer transformation in a world that desperately needs it.

 

Current research with psychedelics is yielding promising results in the treatment of trauma, end of life anxiety, depression and addiction. This wave of resurgence has not come about by chance. At the heart of this psychedelic renaissance is a solid foundation of rigorous scientific studies on these substances and MAPS Canada is the organization that has been spearheading a lot of this important work in Canada.

Currently, MAPS Canada has been supporting studies to legalize MDMA-assisted psychotherapy for the treatment of post-traumatic stress disorders which are now entering into the final phases of clinical trials.

Hear more from Mark Haden, Executive Director of MAPS Canada about the exciting and transformative future of psychedelic treatments in the video above. 

Current Fundraiser Progress

We have currently raised $209,000 towards our new stretch goal of 250k

88%

In collaboration with...